Pharming Group Offers To Acquire Abliva For SEK 0.45/shr In Cash

(RTTNews) - Pharming Group N.V. (PHAR) announced a public cash offer to acquire all issued and outstanding shares of Abliva AB for SEK 0.45 per share in cash. The transaction is valued at approximately US$66.1 million.

The Board of Directors of Abliva recommended the shareholders of Abliva to accept the offer.

The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025.

Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases.